Fig. 1From: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP studyProgression-free survival (a) and overall survival (b) in patients with advanced or recurrent nonsquamous non-small cell lung cancer (n = 40)Back to article page